Ep. 140: “T Cells Under Pressure” Featuring Dr. Martin Prlic
From The Immunology Podcast · · 1 hr 11 min
This plays from the publisher's own server. We do not host a copy.
Description
Guest:
Dr. Martin Prlic is a Professor in the Vaccine and Infectious Disease Division at Fred Hutch Cancer Center. He discusses the challenges of studying human immunology and how his lab uses advanced single-cell technologies to understand T cell responses across healthy, inflamed, and tumor tissues. He also explores the biology of tissue-resident T cells, how inflammation shapes their function, and immune cell interactions at the maternal-fetal interface.
Featured Products and Resources:
- Decorate your lab with a Nature Protocols wallchart outlining the production of therapeutic CAR T cells. (https://www.stemcell.com/t-cell-therapy/products-and-resources)
- Find high-quality antibodies and integrate them into your workflow! (https://www.stemcell.com/products/product-types/antibodies-overview.html)
The Immunology Science Round Up
lncRNA Regulates Gut Immunity (https://www.cell.com/immunity/abstract/S1074-7613(26)00318-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761326003183%3Fshowall%3Dtrue)– An IBD-associated long noncoding RNA promotes immune tolerance by enhancing regulatory T cell function and limiting inflammatory T cell responses.
Trust in Research Antibodies (https://reeserichardson.blog/2026/08/25/at-least-15-companies-are-selling-antibodies-using-faked-validation-data/) – An investigation identified nearly 19,000 apparently manipulated antibody validation images across products sold by 15 research antibody vendors.
Targeting Melanoma with mRNA (https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma) – A Phase III trial found that a personalized mRNA neoantigen therapy combined with KEYTRUDA improved recurrence-free and distant metastasis-free survival compared with KEYTRUDA alone after melanoma surgery.
Beyond Shingles Prevention (https://www.nature.com/articles/s41591-026-04606-0) – A recombinant shingles vaccine was associated with a lower long-term risk of several cardiovascular outcomes, supporting further studies of its potential cardioprotective effects.
Engineering Myeloid Immunotherapy (https://www.cell.com/cell/fulltext/S0092-8674%2826%2900585-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426005854%3Fshowall%3Dtrue) – Expandable granulocyte-monocyte progenitors provide a scalable platform for engineering macrophages that can target blood and solid tumors.
CAR T Cells Meet Glioblastoma (https://www.cell.com/cell/fulltext/S0092-8674%2826%2900643-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426006434%3Fshowall%3Dtrue) – Responses to CAR T cell therapy for glioblastoma are associated with the surrounding immune environment, with NK cells linked to response and regulatory T cells and suppressive myeloid cells linked to resistance.
Image courtesy of Dr. Martin Prlic
Subscribe to our newsletter!
Never miss updates about new episodes.
Subscribe